Inorganic nanohybrids combat antibiotic-resistant bacteria hiding within human macrophages.


Journal

Nanoscale
ISSN: 2040-3372
Titre abrégé: Nanoscale
Pays: England
ID NLM: 101525249

Informations de publication

Date de publication:
07 May 2021
Historique:
pubmed: 23 4 2021
medline: 15 5 2021
entrez: 22 4 2021
Statut: ppublish

Résumé

Bacterial infections are one of the main health concerns humanity faces today and bacterial resistances and protection mechanisms are set to aggravate the issue in the coming years. An increasing number of bacterial strains evades antibiotic treatment by hiding inside cells. Conventional antimicrobial agents are unable to penetrate or be retained in the infected mammalian cells. Recent approaches to overcome these limitations have focused on load-carrier systems, requiring a triggered discharge leading to complex release kinetics. The unison of potent antimicrobial activity with high mammalian cell compatibility is a prerequisite for intracellular activity, which is not well-met by otherwise well-established inorganic systems, such as silver-based nanoparticles. In this work, load and carrier are combined into one functional inorganic nanoparticle system, which unites antimicrobial activity with mammalian cell compatibility. These multicomponent nanohybrids based on cerium oxide are produced in one step, yet unite complex materials. The nanoparticles form suprastructures of similar size and surface charge as bacteria, therefore facilitating the uptake into the same subcellular compartments, where they unleash their antibacterial effect. Such intrinsically antibacterial nanohybrids significantly reduce bacterial survival inside macrophages without harming the latter. Furthermore, blocking of nanoparticle endocytosis and subcellular electron microscopy elucidate the mechanism of action. Taken together, this work presents the first demonstration of antibacterial activity of ceria-based nanoparticles inside of mammalian cells and offers a route to straightforward and robust intracellular antibacterial agents that do not depend on payload delivery or biological constituents.

Identifiants

pubmed: 33885075
doi: 10.1039/d0nr08285f
pmc: PMC8101700
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8224-8234

Références

Cell Commun Signal. 2018 Apr 24;16(1):17
pubmed: 29690889
Acta Biomater. 2016 Dec;46:308-322
pubmed: 27639312
Sci Rep. 2015 Aug 27;5:13500
pubmed: 26311631
Biomaterials. 2015 Sep;62:147-54
pubmed: 26056725
Nanomedicine (Lond). 2015 Oct;10(19):3033-3055
pubmed: 26420270
Acta Biomater. 2015 Feb;13:1-15
pubmed: 25462853
Adv Healthc Mater. 2013 Dec;2(12):1591-9
pubmed: 23630084
Cell Microbiol. 2016 Jan;18(1):80-96
pubmed: 26248337
Front Immunol. 2017 Oct 24;8:1368
pubmed: 29114249
Infect Immun. 2016 Nov 18;84(12):3313-3327
pubmed: 27600508
Nature. 2012 Nov 1;491(7422):31-3
pubmed: 23128209
Nanoscale. 2013 Jul 7;5(13):6063-73
pubmed: 23719690
Trends Microbiol. 2009 Feb;17(2):59-65
pubmed: 19208480
J Immunol. 2000 Apr 1;164(7):3713-22
pubmed: 10725730
ACS Appl Mater Interfaces. 2019 Jan 23;11(3):2830-2839
pubmed: 30571079
Adv Sci (Weinh). 2020 Jun 18;7(15):2000912
pubmed: 32775166
J Exp Med. 2016 Jun 27;213(7):1141-51
pubmed: 27325887
Med Clin North Am. 1982 Jan;66(1):303-12
pubmed: 7038338
Infect Immun. 2006 Aug;74(8):4950-3
pubmed: 16861688
Mater Sci Eng C Mater Biol Appl. 2014 Nov;44:278-84
pubmed: 25280707
Annu Rev Pathol. 2016 May 23;11:343-64
pubmed: 26925499
Nanoscale. 2017 Jun 22;9(24):8418-8426
pubmed: 28604885
J Infect Dis. 2010 Jan 15;201(2):223-32
pubmed: 20001600
Front Cell Infect Microbiol. 2012 Apr 24;2:43
pubmed: 22919634
Nat Commun. 2019 Dec 19;10(1):5783
pubmed: 31857577
N Engl J Med. 1998 Aug 20;339(8):520-32
pubmed: 9709046
Front Microbiol. 2017 Jul 19;8:1354
pubmed: 28769913
Elife. 2016 Feb 26;5:
pubmed: 26919282
J Bacteriol. 2007 Feb;189(3):1025-35
pubmed: 17114262
Toxicol Lett. 2014 Mar 21;225(3):422-32
pubmed: 24463055
Clin Microbiol Rev. 2012 Apr;25(2):362-86
pubmed: 22491776
PLoS One. 2018 Nov 26;13(11):e0207802
pubmed: 30475867
Small. 2013 Aug 12;9(15):2576-84
pubmed: 23418027
Sci Rep. 2016 Jan 05;6:18877
pubmed: 26728712
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3296-302
pubmed: 17048550
Sci Rep. 2017 Apr 07;7:45859
pubmed: 28387344
Infect Immun. 2005 Aug;73(8):4834-45
pubmed: 16040997
Br J Pharmacol. 2017 Jul;174(14):2225-2236
pubmed: 27925153
ACS Appl Mater Interfaces. 2018 May 2;10(17):14299-14311
pubmed: 29633833
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S350-9
pubmed: 18462090
PLoS One. 2010 Jan 13;5(1):e8668
pubmed: 20084270
Appl Environ Microbiol. 2010 Dec;76(24):7981-9
pubmed: 20952651
Nano Lett. 2005 Dec;5(12):2573-7
pubmed: 16351218
ACS Nano. 2017 Dec 26;11(12):12210-12218
pubmed: 29182310
ACS Nano. 2012 May 22;6(5):4349-68
pubmed: 22502734
Mol Microbiol. 2005 Feb;55(3):778-87
pubmed: 15661003
J Antimicrob Chemother. 2019 Jun 1;74(6):1578-1585
pubmed: 30778552
J Photochem Photobiol B. 2018 Aug;185:275-282
pubmed: 30012250
Nanotoxicology. 2017 Mar;11(2):147-149
pubmed: 28055261
Microbiology (Reading). 2003 Oct;149(Pt 10):2749-2758
pubmed: 14523108
Sci Technol Adv Mater. 2018 Oct 18;19(1):732-745
pubmed: 30369998
J Dent Res. 2007 Aug;86(8):754-7
pubmed: 17652205
PLoS One. 2008 Jan 09;3(1):e1409
pubmed: 18183290
J Exp Med. 2005 Jul 18;202(2):209-15
pubmed: 16009720
Nano Lett. 2018 Oct 10;18(10):6229-6236
pubmed: 30153415
Angew Chem Int Ed Engl. 2013 Feb 4;52(6):1636-53
pubmed: 23255416

Auteurs

Martin T Matter (MT)

Laboratory for Particles-Biology Interactions, Department of Materials Meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), Lerchenfeldstrasse 5, 9014 St Gallen, Switzerland. inge.herrmann@empa.ch ingeh@ethz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH